Oncotarget has become one of the leading journals in the scientific community due to its ability to weekly publish various developments made under oncology in the universal war against cancer. As a scientific journal that specifically publishes developments in oncology one has to note that oncology is a broad subject and as such has various other multidisciplinary topics within it. In this regard, Oncotarget has committed itself to publish all credible developments and discoveries made by scientist waging war on cancer.
The many examples of subjects encompassed under the field of oncology include neurodegradation, atherosclerosis, lymphocytes, cells, and molecules, cellular functions in cancerous cells, pathways, and microbes. Under all this fields new developments and discoveries that are made every day by scientists who then submit their finding for publication by Oncotarget.
It is important also to note that before any submission is published by Oncotarget, they are first carried through vetting process where the findings submitted are reviewed and ascertained to be true. This at times involves checking through experiments after visiting the scientist before they are published.
After the findings are published, the journal then serves as a medium of transferring the new information to other expert research on the ways of curing cancer. This important as every little development made in any field increases the knowledge that would aid in making further developments on a gradual victory towards curing cancer.
The journal has become a unique source of scientific knowledge for years now due to many attributes such as the journals ability to review any submissions given to them by scientists in the quickest way possible. This aspect ensures that new information in the field of oncology gets conveyed quickly to other scientists in the fastest time possible. For more info about us: https://twitter.com/oncotargetjrnl?lang=en click here.
The ability of the journal to also publish all the new developments under oncology makes it a unique scientific journal as it is broad and many papers are submitted to them, and those that are credible are all published. The other thing specific to the journal is its ability to follow up with new treatments developed for cancer and post them. They post the effects of the new treatment regiments and the response of the patients undergoing the procedures. This ensures that detailed information reaches out to any party waging war on cancer.
Cancer is one of the most talked-about issues in health, and for good reason. With over 13 million cancer patients in the United States alone, it’s no wonder that people are so eager to discuss the topic and try to find solutions for those suffering from the disease. Enter Clay Siegall, CEO of Seattle Genetics, and his team who have been working towards the successful treatment of cancer – specifically Hodgin’s Lymphoma – for years.
A Background in Pharmaceuticals
Siegall has a strong background in pharmaceutical development and has worked with the biggest names in medicine. He’s spent the majority of his professional life developing and testing drugs for cancer patients in the hopes of creating treatments that will improve the prognoses of cancer patients and perhaps one day erradicate the disease entirely. Seigall brought that passion for treatment development to Seattle Genetics and has been working side by side with industry leaders to use genetic and pharmaceutical means to create better, more effective treatments for cancer patients.
A Commitment to a Cure
In the medical field, particularly in the field of cancer research, it takes determination and passion to keep going when the odds seem stacked against success. Clay Siegall is that kind of person, and it’s no surprise that his commitment to a cure and the successful treatment of cancer has carried him this far. Seattle Genetics is already making a name for itself in no small part because of the depth of knowledge and passion that Dr. Siegall brings to the table. Only time will tell what the future holds for cancer treatment.
Clay Siegall Ph.D. is a powerful force in the field of cancer research. He co-founded Seattle Genetics in 1998 where he serves as the company’s CEO, president and the chairman of the board of directors. Seattle Genetics is a company dedicated to finding cures for cancers and in helping to ease the suffering of cancer patients. They have developed a group of antibody-based therapies that specifically attack cancer cells while leaving healthy cells unharmed. Their drug, ADCETRIS which was recently given accelerated approval by the U.S. Food and Drug Administration in 2011 shows incredible promise. Clay Siegall was appointed to the board of directors of Mirna Therapeutics, an Austin, Texas-based company founded in 2007 that like Siegall’s Seattle Genetics is focused on cancer research. Mirna Therapeutics has made advances in the realm of microRNA, an area of keen interest for Siegall. The combining of these two powerful companies researching and developing cures for cancer shows the altruistic goals of both Mirna Therapeutics and Siegall.
Siegall began his interest in oncology as a student at the University of Maryland studying Zoology. Siegall continued his education at George Washington University where he received his Ph.D. in Genetics. Before co-founding Seattle Genetics, he worked for the National Cancer Institute, the National Institute of Health, and the Bristol-Myers Squibb Pharmaceutical Research company. He has written extensively in his field of expertise, publishing 70 works along with obtaining 15 patents in his field of endeavor.
Mirna Therapeutics is fortunate to have Dr. Siegall on its board of directors, and the world is lucky to have a scientist and researcher like Dr. Siegall searching for cures to a terrible disease.
Clay Siegall, the CEO of Seattle Genetics, was appointed as an outside director for Mirna Therapeutics in January of 2013. His colleague (and CEO of Mirna) on the board of directors, Paul Lammers, expressed his excitement at Siegall’s induction to the board that day, citing the Seattle Genetics’ CEO as being an indispensable asset due to his success in the oncology field. Mirna is a company focused on providing cutting-edge MicroRNA (miRNA) Therapy technologies in a commercial capacity, and Clay Siegall’s contributions have helped to further that initiative.
Dr. Clay Siegall helped to build Seattle Genetics from the ground up in 1998, and his leadership proved effective when, in 2011, one of the companies many pharmaceutical candidates, ADCETRIS®, was approved for commercial production. Siegall is known for his drive for well-executed science, and he seamlessly blends this drive with a passion for helping patients with the cancer therapies he has helped to develop. Aside from serving on the board of directors for Mirna Therapeutics, Dr. Siegall has also served on the board of directors for Ultragenyx Pharmaceutical and Alder Biopharmaceuticals Inc.
Clay Siegall earned his Ph.D. in Genetics at The George Washington University and then began applying the knowledge he gained to assisting in the development of diverse and effective targeted cancer therapies. As recent as August 1st, 2016, Seattle Genetics along with Takeda released information surrounding positive data yielded from ADCETRIS tests, further cementing the extent of the contributions made by Siegall.
Siegall’s achievements have netted him awards such as University of Maryland’s 2013 Alumnus of the Year Award for Computer, Math, and Natural Sciences, and Pacific Northwest Ernst $ Young’s 2012 Entrepreneur of the Year award for his work in co-founding Seattle Genetics. In the 18 years during which Clay Siegall has guided the efforts of Seattle Genetics, he has brought the company from a startup with big dreams, to a company working on the forefront of cancer therapy pharmaceuticals and research. The world of active cancer therapy research would be a different place without the contributions of Dr. Siegall; Seattle Genetics is fortunate to have him.